- Flash glucose monitoring (FGM) -based program will enable BeatO members to get actionable insights from BeatO’s team of experts basis continuous data from their flash glucose monitors
- Provides real-time actionable insights on diet, lifestyle and medication based on data from the FGM system
- Enables holistic patient management to help members manage glucose fluctuations
Mumbai, June 28, 2021: Owing to the rising complications arising out of uncontrolled diabetes, India’s leading digital care ecosystem for chronic condition management, BeatO has today announced the launch of a flash glucose monitoring program for better data-driven prevention, control and reversal of Diabetes. This will enable users to better assess their relationship with food and get targeted diet, lifestyle and medication counselling from BeatO’s team of doctors and experts based on their FGM data.
A flash glucose monitor uses a sensor that is placed on the back of the upper arm and worn externally by the user, allowing glucose information to be monitored using a FGM reader. Data from the FGM will enable healthcare professionals at BeatO to observe trends and provide patient-specific insights to achieve targeted HbA1c levels. BeatO will be using FGM devices of Abbott, the world-leader in sensor-based technology.
Under the current scenario of COVID-19, increased glucose levels and onset of diabetes has been observed as an after-effect during COVID-19 recovery. Post-COVID complications such as mucormycosis have also seen rampant rise in the past few weeks which is caused due to uncontrolled diabetes among other issues. It has been also noted that timely advice and management has accelerated post-COVID recovery, compared to recovery delays of up to 3 months in other cases. This calls for a need of continuous monitoring and precise decision making across food, lifestyle and medication based on one’s glucose levels. Continuous feedback from BeatO’s in-house nutrition analysts, coaches and doctors based on the user’s dynamic glucose readings can improve glycemic control and avert complications arising from the condition.
Speaking on the launch, Gautam Chopra, Co-founder & CEO, BeatO said “Abbott’s world-leading Flash Glucose Monitoring technology with BeatO’s app ecosystem will give our members precise data, along with actionable insights to effectively prevent, control or reverse their diabetes. Our FGM enabled program is an extension of our vision to empower our members with the right decision-making support for their health”
This integration of the FGM with BeatO’s app ecosystem will enable holistic patient management which will help users to understand their relationship with food vis-à-vis glucose fluctuations like hypoglycemia, hyperglycemia and overall take better control of their condition. Being one of India’s largest digital health platform for chronic conditions, BeatO provides effective and evidence-based insights to users based on their glucose readings.